Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually have functional repair defects remains unknown. Here, we devise a platform for functional profiling of DNA repair in short-term patient-derived HGSC organoids. We tested 33 organoid cultures derived from 22 patients with HGSC for defects in homologous recombination (HR) and replication fork protection. Regardless of DNA repair gene mutational status, a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity. A functional defect in replication fork protection correlated with carboplatin and CHK1 and ATR inhibitor sensitivity. Our results indicate that a combination of genomic analysis and functional testing of organoids allows for the identification of targetable DNA damage repair defects. Larger numbers of patient-derived organoids must be analyzed to determine whether these assays can reproducibly predict patient response in the clinic. Significance: Patient-derived ovarian tumor organoids grow rapidly and match the tumors from which they are derived, both genetically and functionally. These organoids can be used for DNA repair profiling and therapeutic sensitivity testing and provide a rapid means of assessing targetable defects in the parent tumor, offering more suitable treatment options. Cancer Discov; 8(11); 1404–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [125]
In the citing paper
“PDOs are a validated preclinical model to evaluate anti-cancer drug efficacy [24,25].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [24]
In the citing paper
“Patient-derived organoids or tumoroids retain cellular heterogeneity and immune cells, thus are able to more strongly recapitulate a three-dimensional (3D) tumor microenvironment ex vivo compared to homogeneous cell lines (Hill et al., 2018; Kopper et al., 2019).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“Ovarian tumoroid cultures have been established from both ascitic fluid and primary tumors, to date primarily from the more common HGSOC but also from LGSOC, MOC, OCCC, and EnOC (Hill et al., 2018; De Witte et al., 2020; Nanki et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“In contrast, it has been noted that organoid propagation methods tend to be selective and result in a cell population that may not be representative of the original tumor heterogeneity and in turn, treatment response, particularly in patients who have undergone previous neoadjuvant therapy (Hill et al., 2018).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 2×
“2 and Table 1), because olaparib sensitivity is a useful surrogate marker for an HR defect (7).”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“Large-scale studies of organoids, with comparison with patient outcomes, will be required to prove the utility of this model system in the clinic (18, 19, 21).”
ResultWhole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569 · cited 2×
“NOVEMBER 2018 CANCER DISCOVERY | 1419 Human tumors derived from several tissue types exhibit clonal heterogeneity (22, 46), and functional assays in organoids can be used to address the effects of genomic tumor heterogeneity on therapeutic response.”
BackgroundOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., & Jasin, M. (2011) · Cell · doi:10.1016/j.cell.2011.03.041 · Cited by 1,255
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117 · cited 2×
“Even many of these patients do not respond (31, 32, 36).”
BackgroundHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · cited 2×
“Even in this small data set, the functional results indicate that a BRCA1/2 or Fanconi anemia pathway mutation is neither necessary nor sufficient for conferring an HR defect and PARPi sensitivity (4, 7, 10, 38).”
BackgroundSelf-citationPersonalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1154 · Cited by 937 · cited 1×
“Large-scale studies of organoids, with comparison with patient outcomes, will be required to prove the utility of this model system in the clinic (18, 19, 21).”
ResultReplication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Self-citationTumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Disease modeling in stem cell-derived 3D organoid systems
Dutta, D., Heo, I., & Clevers, H. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.02.007 · Cited by 838 · cited 1×
“Large-scale studies of organoids, with comparison with patient outcomes, will be required to prove the utility of this model system in the clinic (18, 19, 21).”
ResultThe essential kinase ATR: ensuring faithful duplication of a challenging genome
Saldivar, J. C., Cortez, D., & Cimprich, K. A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.67 · Cited by 838
The Fanconi anaemia pathway: new players and new functions
Ceccaldi, R., Sarangi, P., & D'Andrea, A. D. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.48 · Cited by 720 · cited 2×
“In the process of HR, RAD51 is loaded onto the ends of a double-strand break (DSB), allowing the resected DSB to invade the sister chromatid (6).”
BackgroundSelf-citationSignatures of mutation and selection in the cancer genome
Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08768 · Cited by 707
Organoid culture systems for prostate epithelial and cancer tissue
Drost, J., Karthaus, W. R., Gao, D., Driehuis, E., Sawyers, C. L., Chen, Y., & Clevers, H. (2016) · Nature Protocols · doi:10.1038/nprot.2016.006 · Cited by 699
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594 · cited 1×
“Additionally, although ovarian organoid cultures contain a minimal stromal component and do not faithfully mimic all components of the tumor microenvironment, organoids do contain immune cells (20), and may be useful in studying the immune intereaction with the tumor in real time.”
BackgroundLiu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585 · cited 1×
“Clinical trials have suggested that some “sporadic” HGSC cases have PARPi response (31, 32); however, the stronger responses occur mostly in BRCA or other repair gene mutation carriers with monotherapy (8, 33) or in combination with other therapies (34, 35).”
BackgroundSelf-citationSandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562 · cited 2×
“Even many of these patients do not respond (31, 32, 36).”
BackgroundLedermann, J. A., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30376-x · Cited by 450
Self-citationYazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 395
Self-citationCan advanced-stage ovarian cancer be cured?
Narod, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.224 · Cited by 369
Rondinelli, B., Gogola, E., Yücel, H., Duarte, A. A., van de Ven, M., van der Sluijs, R., Konstantinopoulos, P. A., Jonkers, J., Ceccaldi, R., Rottenberg, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3626 · Cited by 332 · cited 1×
“BRCA1 and BRCA2 have additional roles in the protection of stalled replication forks, discrete from their functions in HR (11, 24, 25, 39).”
BackgroundSelf-citationPathogenesis and heterogeneity of ovarian cancer
Kroeger, P. T., & Drapkin, R. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000340 · Cited by 314
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L., Barrett, A., Kraya, A. A., Anastopoulos, I. N., Yu, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00388-9 · Cited by 296 · cited 1×
“BRCA1 mutation carriers without loss of the wild-type allele and with intact HR, based on genomic analysis, have been observed previously (29).”
MethodScreening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2018) · JAMA · doi:10.1001/jama.2017.21926 · Cited by 283
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C., van der Heijden, I., van der Gulden, H., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 262 · cited 1×
“C61G mutation has been shown to be sufficient for tumorigenesis but not for platinum or PARPi sensitivity, suggesting that even in the absence of wild-type protein expression, this hypomorph may have functional DNA repair activity (30).”
BackgroundGermline RAD51C mutations confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (BCSC) (UK), Loveday, C., Turnbull, C., Ruark, E., Xicola, R. M. M., Ramsay, E., Hughes, D., Warren-Perry, M., Snape, K., Eccles, D., et al. (2012) · Nature Genetics · doi:10.1038/ng.2224 · Cited by 252
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Etemadmoghadam, D., Weir, B. A., Au-Yeung, G., Alsop, K., Mitchell, G., George, J., Australian Ovarian Cancer Study Group, Davis, S., D’Andrea, A. D., Simpson, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314302110 · Cited by 225
Self-citationLee, J.-M., Nair, J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., Merino, M. J., Swisher, E. M., Harrell, M. I., Trepel, J. B., Lee, M.-J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30009-3 · Cited by 209
Self-citationGenetic insights into the morass of metastatic heterogeneity
Hunter, K. W., Amin, R., Deasy, S., Ha, N.-H., & Wakefield, L. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.126 · Cited by 163 · cited 1×
“NOVEMBER 2018 CANCER DISCOVERY | 1419 Human tumors derived from several tissue types exhibit clonal heterogeneity (22, 46), and functional assays in organoids can be used to address the effects of genomic tumor heterogeneity on therapeutic response.”
BackgroundPARP inhibitors in ovarian cancer: Current status and future promise
Liu, J. F., Konstantinopoulos, P. A., & Matulonis, U. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.039 · Cited by 161 · cited 1×
“Clinical trials have suggested that some “sporadic” HGSC cases have PARPi response (31, 32); however, the stronger responses occur mostly in BRCA or other repair gene mutation carriers with monotherapy (8, 33) or in combination with other therapies (34, 35).”
BackgroundSelf-citationThe DNA fibre technique – tracking helicases at work
Nieminuszczy, J., Schwab, R. A., & Niedźwiedź, W. (2016) · Methods · doi:10.1016/j.ymeth.2016.04.019 · Cited by 142
BRCA1 Is Required for Postreplication Repair after UV-Induced DNA Damage
Pathania, S., Nguyen, J., Hill, S. J., Scully, R., Adelmant, G., Marto, J. A., Feunteun, J., & Livingston, D. M. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.09.002 · Cited by 136 · cited 2×
“BRCA1 and BRCA2 have additional roles in the protection of stalled replication forks, discrete from their functions in HR (11, 24, 25, 39).”
BackgroundSelf-citationCisplatin Resistance and Transcription Factors
Torigoe, T., Izumi, H., Ishiguchi, H., Yoshida, Y., Tanabe, M., Yoshida, T., Igarashi, T., Niina, I., Wakasugi, T., Imaizumi, T., et al. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053352587 · Cited by 133
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Self-citationBryant, C., Rawlinson, R., & Massey, A. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-570 · Cited by 125 · cited 1×
“Prexasertib primes a tumor for sensitivity to other DNArepair agents by blocking the ATR/CHK1 pathway, thereby increasing RS (12, 41).”
BackgroundDean, E., Middleton, M. R., Pwint, T., Swaisland, H., Carmichael, J., Goodege-Kunwar, P., & Ranson, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.555 · Cited by 123 · cited 1×
“Clinical trials have suggested that some “sporadic” HGSC cases have PARPi response (31, 32); however, the stronger responses occur mostly in BRCA or other repair gene mutation carriers with monotherapy (8, 33) or in combination with other therapies (34, 35).”
BackgroundMorphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam, P. (2016) · PubMed · Cited by 106
Distinct Roles of FANCO/RAD51C Protein in DNA Damage Signaling and Repair
Somyajit, K., Subramanya, S., & Nagaraju, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311241 · Cited by 85 · cited 1×
“The HRD mutational signature was strongest in patient DF-17-126, the patient with a germline mutation in RAD51C/ FANCO, an ovarian cancer susceptibility gene required for HR repair (27, 28).”
BackgroundJenner, Z. B., Sood, A. K., & Coleman, R. L. (2016) · Future Oncology · doi:10.2217/fon-2016-0002 · Cited by 77
Targeting DNA repair and replication stress in the treatment of ovarian cancer
Murai, J. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1145-7 · Cited by 76
AlHilli, M. M., Becker, M. A., Weroha, S. J., Flatten, K. S., Hurley, R. M., Harrell, M. I., Oberg, A. L., Maurer, M. J., Hawthorne, K. M., Hou, X., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.328 · Cited by 73 · cited 2×
“WES data combined with the functional assays suggest that even if a patient harbors a germline mutation in an HR gene and exhibits copy-number loss of the wild-type allele or an HRD mutational signature, the tumor cells may not be sensitive to therapies predicted by the mutation (38).”
BackgroundSelf-citationFirst-line treatment of ovarian cancer: questions and controversies to address
Ledermann, J. A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918768232 · Cited by 51 · cited 1×
“Larger ongoing trials will determine the response rate in true sporadic patients (37).”
BackgroundKochupurakkal, B. S., Parmar, K., Lazaro, J., Unitt, C., Zeng, Q., Reavis, H. D., Ganesa, C., Zhou, S., Liu, J. F., Palakurthi, S. S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2796 · Cited by 13 · cited 1×
“Organoid cultures were treated with 0 or 10 Gy, prior to assaying for RAD51 foci (23).”
MethodSelf-citation
Cited by
Cancer modeling meets human organoid technology
Tuveson, D., & Clevers, H. (2019) · Science · doi:10.1126/science.aaw6985 · Cited by 935
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.10.010 · Cited by 755
Establishment of patient-derived cancer organoids for drug-screening applications
Driehuis, E., Kretzschmar, K., & Clevers, H. (2020) · Nature Protocols · doi:10.1038/s41596-020-0379-4 · Cited by 654
Human Organoids: Tools for Understanding Biology and Treating Diseases
Schutgens, F., & Clevers, H. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032611 · Cited by 510
Metadata
- Authors
- Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., Yang, C., Morizane, R., Kochupurakkal, B. S., Do, K. T., Konstantinopoulos, P. A., Liu, J. F., Bonventre, J. V., Matulonis, U. A., Shapiro, G. I., Berkowitz, R. S., Crum, C. P., & D'Andrea, A. D.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- 1Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- ORCID
- Hill, Sarah J.
- Decker, Brennan
- Roberts, Emma A.
- Horowitz, Neil S.
- Worley, Michael J.
- Feltmate, Colleen M.
- Nucci, Marisa R.
- Swisher, Elizabeth M.
- Nguyen, Huy
- Yang, Chunyu
- Morizane, Ryuji
- Kochupurakkal, Bose S.
- Do, Khanh T.
- Konstantinopoulos, Panagiotis A.
- Liu, Joyce F.
- Bonventre, Joseph V.
- Matulonis, Ursula A.
- Shapiro, Geoffrey I.
- Berkowitz, Ross S.
- Crum, Christopher P.
- Venue
- Cancer Discovery
- Published
- 2018-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1404-1421
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6365285
- OpenAlex
- W2891058330
- Cited by
- 452
- References
- 49
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 67 · 2023: 78 · 2022: 66 · 2021: 72 · 2020: 63 · 2019: 25 · 2018: 1
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Stand Up to Cancer (SU2C) (SU2C-AACR-DT16-15)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (R37HL052725, P01HL048546)
- U.S. Department of Defense (DOD) (BC151331P1)
- Leukemia and Lymphoma Society (LLS) (6237-13)
- Breast Cancer Research Foundation (BCRF)
- Richard and Susan Smith Family Foundation
- The Bridge Project
- HHS | NIH | National Cancer Institute (NCI) (UM1 CA186709)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- high-grade serous ovarian cancer, DNA repair deficiency, patient-derived tumor organoids, homologous recombination deficiency, replication fork protection, PARP inhibitor sensitivity, carboplatin sensitivity, CHK1 inhibitor, ATR inhibitors, predictive biomarkers, targeted therapy
- MeSH terms
- Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, DNA Repair, DNA Replication, Female, Follow-Up Studies, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Organ Culture Techniques, Organoids, Ovarian Neoplasms, Prognosis, Pyrazines, Pyrazoles, Biomarkers, Tumor, Carboplatin, Cystadenocarcinoma, Serous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.